Julian Adams - Infinity Pharmaceuticals President of RandD
| INFIDelisted Stock | USD 0.04 0.03 42.86% |
President
Dr. Julian Adams Ph.D. is President Research Development of Infinity Pharmaceuticals Inc. since October 2007. He has served as our President of Research Development since October 2007 our Chief Scientific Officer between September 2006 and May 2010 as Chief Scientific Officer of IPI from October 2003 until the merger with DPI in September 2006 as our President between September 2006 and October 2007 and as President of IPI from February 2006 until September 2006. Prior to joining Infinity Dr. Adams served as Senior Vice President Drug Discovery and Development at Millennium Pharmaceuticals Inc. from 1999 to 2001 where he led the development of bortezomib also known as Velcade. Dr. Adams served as Senior Vice President Research and Development at LeukoSite Inc. a private biopharmaceutical company from July 1999 until its acquisition by Millennium in December 1999. Dr. Adams served as a director and Executive Vice President of Research and Development at ProScript Inc. a private biopharmaceutical company from 1994 until its acquisition by LeukoSite in 1999. Prior to joining ProScript Dr. Adams held a variety of positions with Boehringer Ingelheim a private pharmaceutical company and Merck Co. Inc. a publicly traded pharmaceutical company. Dr. Adams has served as a director of Aileron Therapeutics Inc. a privately held biopharmaceutical company between 2011 and 2013 a director of Warp Drive Bio LLC since 2013 and a director of the Princess Margaret Cancer Foundation since November 2014 since 2010.
| Age | 60 |
| Tenure | 14 years |
| Phone | 617 453 1000 |
| Web | https://www.infi.com |
Julian Adams Latest Insider Activity
Tracking and analyzing the buying and selling activities of Julian Adams against Infinity Pharmaceuticals stock is an integral part of due diligence when investing in Infinity Pharmaceuticals. Julian Adams insider activity provides valuable insight into whether Infinity Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Infinity Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Infinity Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Julian Adams over a year ago Acquisition by Julian Adams of 28300 shares of Gamida Cell subject to Rule 16b-3 |
Infinity Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.607) % which means that it has lost $0.607 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (35.2135) %, meaning that it created substantial loss on money invested by shareholders. Infinity Pharmaceuticals' management efficiency ratios could be used to measure how well Infinity Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 917 K in liabilities with Debt to Equity (D/E) ratio of 0.13, which may suggest the company is not taking enough advantage from borrowing. Infinity Pharmaceuticals has a current ratio of 4.08, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Infinity Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Infinity Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Infinity Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Infinity to invest in growth at high rates of return. When we think about Infinity Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Lloyd Rowland | CytomX Therapeutics | 61 | |
| Pinaki Niyogy | Instil Bio | 46 | |
| Steven Perrin | Eledon Pharmaceuticals | 58 | |
| Cynthia Ladd | CytomX Therapeutics | 61 | |
| Christopher Keenan | CytomX Therapeutics | N/A | |
| Steven Knox | Assembly Biosciences | N/A | |
| Uri Lopatin | Assembly Biosciences | 45 | |
| Leslie Robbins | CytomX Therapeutics | N/A | |
| Heather KnightTrent | Chimerix | N/A | |
| Bonne Adams | TRACON Pharmaceuticals | 47 | |
| Timothy Trost | Chimerix | 55 | |
| Jacqueline Papkoff | Assembly Biosciences | 61 | |
| David Houck | Assembly Biosciences | 61 | |
| Janet LeeSheriff | Instil Bio | N/A | |
| Nick Galli | CytomX Therapeutics | N/A | |
Management Performance
| Return On Equity | -35.21 | |||
| Return On Asset | -0.61 |
Infinity Pharmaceuticals Leadership Team
Elected by the shareholders, the Infinity Pharmaceuticals' board of directors comprises two types of representatives: Infinity Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Infinity. The board's role is to monitor Infinity Pharmaceuticals' management team and ensure that shareholders' interests are well served. Infinity Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Infinity Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joseph Pearlberg, Vice President - Clinical Development | ||
| Melissa Hackel, Vice President - Finance | ||
| William Bertrand, Executive Vice President General Counsel | ||
| Vito Palombella, Chief Scientific Officer and Executive VP | ||
| Jeffrey Berkowitz, Independent Director | ||
| Seth JD, Chief VP | ||
| Lawrence Bloch, CFO, Executive Vice President Chief Business Officer | ||
| Norman Selby, Lead Outside Independent Director | ||
| Jose Baselga, Independent Director | ||
| Samuel Agresta, Chief Medical Officer | ||
| Michael Venuti, Independent Director | ||
| Stephane Peluso, Chief Officer | ||
| MD Ilaria, Chief Officer | ||
| Jayne Kauffman, Sr Coordinator | ||
| Michael Kauffman, Independent Director | ||
| Eric Lander, Independent Director | ||
| David Beier, Independent Director | ||
| Julian Adams, President of RandD | ||
| Anthony Evnin, Independent Director | ||
| Gwendolyn Fyfe, Independent Director | ||
| Sujay Kango, Executive Vice President Chief Commercial Officer | ||
| Ian Smith, Independent Director | ||
| Adelene Perkins, Chairman of The Board, CEO and Pres | ||
| MD JD, Pres Treasurer |
Infinity Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Infinity Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -35.21 | |||
| Return On Asset | -0.61 | |||
| Operating Margin | (15.70) % | |||
| Current Valuation | (9.46 M) | |||
| Shares Outstanding | 90.76 M | |||
| Shares Owned By Insiders | 2.36 % | |||
| Shares Owned By Institutions | 23.48 % | |||
| Number Of Shares Shorted | 2.21 M | |||
| Price To Earning | (1.63) X | |||
| Price To Book | 8.03 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the Infinity Pharmaceuticals information on this page should be used as a complementary analysis to other Infinity Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Other Consideration for investing in Infinity Stock
If you are still planning to invest in Infinity Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Infinity Pharmaceuticals' history and understand the potential risks before investing.
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |